Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

Pre-analytical phase challenges & biomarker testing in HER2+ metastatic breast cancer From Prof. Gary Tse, Dr Carlos Barrios, & Oncology Brothers Highlights in this video 📹 >> Endorsed by Biomarker Collaborative Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.

BreastCaConnect's profile picture

BREAST CANCER CONNECT powered by COR2ED

2,395 subscribers

15,267,076 Aufrufe • vor 17 Tagen •via X (Twitter)

Wissenschaft & TechnologieGesundheit & Wellness
LIVE

Anya Rossi• Live Now

Private livecam show

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

Are ADCs the next therapeutic options for pts w/ pretreated HR+/HER2- (IHC 0) metastatic breast cancer who have developed an endocrine resistance? Find out as you follow a pt journey in this case-based video Endorsed by ICAN, International Cancer Advocacy Network Biomarker Collaborative GRASP & Exon 20 Group, a multistakeholder organization Supported by an Independent Educational Grant from AstraZeneca.
9:15

Are ADCs the next therapeutic options for pts w/ pretreated HR+/HER2- (IHC 0) metastatic breast cancer who have developed an endocrine resistance? Find out as you follow a pt journey in this case-based video Endorsed by ICAN, International Cancer Advocacy Network Biomarker Collaborative GRASP & Exon 20 Group, a multistakeholder organization Supported by an Independent Educational Grant from AstraZeneca.

BREAST CANCER CONNECT

1,019,784 Aufrufe • vor 10 Monaten

HER2+ metastatic breast cancer How can we manage TRAEs e.g. N+V/fatigue/ILD? 📺 Video from Prof. Javier Cortes MD PhD Supported by an Independent Educational Grant from AstraZeneca
3:33

HER2+ metastatic breast cancer How can we manage TRAEs e.g. N+V/fatigue/ILD? 📺 Video from Prof. Javier Cortes MD PhD Supported by an Independent Educational Grant from AstraZeneca

BREAST CANCER CONNECT powered by COR2ED

5,825,154 Aufrufe • vor 2 Monaten

ADCs in HER2+ metastatic breast cancer: management of adverse events Get step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC > N/V > Fatigue > Interstitial lung disease (rare but critical) From Prof. Shaheenah Dawood, Dr Sara Tolaney, Prof. Javier Cortes MD PhD, Carla Whitbread, Dr Grazyna Suchodolska & Prof. Giuseppe Curigliano Endorsed by the European Oncology Nursing Society (@cancernurseEU) and Europa Donna Supported by an Independent Educational Grant from AstraZeneca
3:41

ADCs in HER2+ metastatic breast cancer: management of adverse events Get step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC > N/V > Fatigue > Interstitial lung disease (rare but critical) From Prof. Shaheenah Dawood, Dr Sara Tolaney, Prof. Javier Cortes MD PhD, Carla Whitbread, Dr Grazyna Suchodolska & Prof. Giuseppe Curigliano Endorsed by the European Oncology Nursing Society (@cancernurseEU) and Europa Donna Supported by an Independent Educational Grant from AstraZeneca

BREAST CANCER CONNECT powered by COR2ED

7,263,743 Aufrufe • vor 4 Monaten

Personalised treatment in childhood cancer: A journey through 𝘕𝘛𝘙𝘒 fusion testing 📺Video for patients & families – please share with your network From Linet Menachery, patient advocate and mother of a child diagnosed with an 𝘕𝘛𝘙𝘒 fusion-positive pediatric cancer Endorsed by NTRKers, ICAN, International Cancer Advocacy Network & Biomarker Collaborative Supported by an Independent Educational Grant from Bayer
4:51

Personalised treatment in childhood cancer: A journey through 𝘕𝘛𝘙𝘒 fusion testing 📺Video for patients & families – please share with your network From Linet Menachery, patient advocate and mother of a child diagnosed with an 𝘕𝘛𝘙𝘒 fusion-positive pediatric cancer Endorsed by NTRKers, ICAN, International Cancer Advocacy Network & Biomarker Collaborative Supported by an Independent Educational Grant from Bayer

COR2ED

5,214,734 Aufrufe • vor 3 Monaten

Managing ADC toxicities in HER2+ metastatic breast cancer - spotlight on nausea & vomiting Nausea/vomiting are common AEs associated with ADCs, particularly T-DXd, along with fatigue ILD, while less common, is an AE of special interest How can you manage N/V and more in clinical practice? Get step-by-step guidance from Dr Sara Tolaney Endorsed by ICAN, International Cancer Advocacy Network Supported by an Independent Educational Grant from AstraZeneca
6:39

Managing ADC toxicities in HER2+ metastatic breast cancer - spotlight on nausea & vomiting Nausea/vomiting are common AEs associated with ADCs, particularly T-DXd, along with fatigue ILD, while less common, is an AE of special interest How can you manage N/V and more in clinical practice? Get step-by-step guidance from Dr Sara Tolaney Endorsed by ICAN, International Cancer Advocacy Network Supported by an Independent Educational Grant from AstraZeneca

BREAST CANCER CONNECT powered by COR2ED

528,125 Aufrufe • vor 8 Monaten

ER+/HER2- metastatic breast cancer: Highlights from APBCS 2026 Satellite Symposium, chaired by Dr Mastura Md Yusof 📺 Experts discuss 2L+ treatment strategies in endocrine therapy-eligible patients From Dr Hope S. Rugo (Hope Rugo) and Prof. Matteo Lambertini (Matteo Lambertini, MD PhD) This programme has been sponsored by Menarini Stemline and is intended for HCPs only. Brought to you by COR2ED Medical Affairs
4:58

ER+/HER2- metastatic breast cancer: Highlights from APBCS 2026 Satellite Symposium, chaired by Dr Mastura Md Yusof 📺 Experts discuss 2L+ treatment strategies in endocrine therapy-eligible patients From Dr Hope S. Rugo (Hope Rugo) and Prof. Matteo Lambertini (Matteo Lambertini, MD PhD) This programme has been sponsored by Menarini Stemline and is intended for HCPs only. Brought to you by COR2ED Medical Affairs

COR2ED

7,632,504 Aufrufe • vor 4 Monaten

🧬Precision oncology in HR+/HER2- metastatic #breastcancer. Dr Callahan and Dr Salgado discuss: Essential #biomarkers (ESR1m, PIK3CA, gBRCA) and their clinical implications, Liquid vs tumour biopsy – when and how? Single gene vs broad panel testing…and much more! 📹 Watch the video highlights in this post 🗣️Get the full conversation/listen to the audio on Spotify/Apple: Supported by an Independent Educational Grant from Thermo Fisher Scientific #MedEd #BCSM #OncTwitter
5:51

🧬Precision oncology in HR+/HER2- metastatic #breastcancer. Dr Callahan and Dr Salgado discuss: Essential #biomarkers (ESR1m, PIK3CA, gBRCA) and their clinical implications, Liquid vs tumour biopsy – when and how? Single gene vs broad panel testing…and much more! 📹 Watch the video highlights in this post 🗣️Get the full conversation/listen to the audio on Spotify/Apple: Supported by an Independent Educational Grant from Thermo Fisher Scientific #MedEd #BCSM #OncTwitter

BREAST CANCER CONNECT

112,471 Aufrufe • vor 1 Jahr

GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) Dr. Shubham Pant & Prof. Efrat Dotan MD discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of toxicities - Strategies to manage side effects 📹 Highlights video in this post Endorsed by ICAN, International Cancer Advocacy Network Digestive Cancers Europe The National Pancreas Foundation PanCAN Supported by an Independent Educational Grant from Ipsen USA
4:31

GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) Dr. Shubham Pant & Prof. Efrat Dotan MD discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of toxicities - Strategies to manage side effects 📹 Highlights video in this post Endorsed by ICAN, International Cancer Advocacy Network Digestive Cancers Europe The National Pancreas Foundation PanCAN Supported by an Independent Educational Grant from Ipsen USA

GI CONNECT powered by COR2ED

1,202,819 Aufrufe • vor 8 Monaten

🧬 What do HCPs need to know about current treatment options for advanced/recurrent #EndometrialCancer? An animated #MedEd video from Prof. Christian Marth 📺 Hear about 👉 A patient case study 👉 Latest treatment strategies 👉 A shift from traditional chemotherapy to personalised therapies driven by molecular profiling. This educational programme is sponsored by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme. #Oncology #GynecologicCancer
7:36

🧬 What do HCPs need to know about current treatment options for advanced/recurrent #EndometrialCancer? An animated #MedEd video from Prof. Christian Marth 📺 Hear about 👉 A patient case study 👉 Latest treatment strategies 👉 A shift from traditional chemotherapy to personalised therapies driven by molecular profiling. This educational programme is sponsored by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme. #Oncology #GynecologicCancer

OBSTETRICS & GYNECOLOGY CONNECT

462,512 Aufrufe • vor 1 Jahr

Update from ESMO 2025! >> Endometrial & ovarian cancer highlights 📺 Prof. Nicoletta Colombo reviews the latest data in gynecological cancers presented at the congress Could these developments impact clinical practice? Watch to find out! Endorsed by ICAN, International Cancer Advocacy Network This independent programme is supported by COR2ED
5:30

Update from ESMO 2025! >> Endometrial & ovarian cancer highlights 📺 Prof. Nicoletta Colombo reviews the latest data in gynecological cancers presented at the congress Could these developments impact clinical practice? Watch to find out! Endorsed by ICAN, International Cancer Advocacy Network This independent programme is supported by COR2ED

COR2ED

114,711 Aufrufe • vor 8 Monaten

🧬 What do HCPs need to know about current treatment options for advanced/recurrent EndometrialCancer? An animated MedEd video from Prof. Christian Marth 📺 Hear about 👉 A patient case study 👉 Latest treatment strategies 👉 A shift from traditional chemotherapy to personalised therapies driven by molecular profiling. This educational programme is sponsored by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme.
7:36

🧬 What do HCPs need to know about current treatment options for advanced/recurrent EndometrialCancer? An animated MedEd video from Prof. Christian Marth 📺 Hear about 👉 A patient case study 👉 Latest treatment strategies 👉 A shift from traditional chemotherapy to personalised therapies driven by molecular profiling. This educational programme is sponsored by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme.

OBSTETRICS & GYNECOLOGY CONNECT powered by COR2ED

240,514 Aufrufe • vor 1 Jahr

Just released! Bladder cancer update from ESMO 25 📺 Prof. Thomas Powles shares his bladder cancer highlights & reviews the latest data from KEYNOTE-905, ALBAN & Imvigor011. This independent programme is supported by COR2ED
4:24

Just released! Bladder cancer update from ESMO 25 📺 Prof. Thomas Powles shares his bladder cancer highlights & reviews the latest data from KEYNOTE-905, ALBAN & Imvigor011. This independent programme is supported by COR2ED

COR2ED

229,737 Aufrufe • vor 8 Monaten

LEVIATHAN publication snapshot >> Expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for HCC 📺 from Prof. David Pinato (David James Pinato 🇺🇦) >> Programme endorsed by European Liver Patients' Association, Blue Faery, Global Liver Institute & ESDO This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content.
4:29

LEVIATHAN publication snapshot >> Expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for HCC 📺 from Prof. David Pinato (David James Pinato 🇺🇦) >> Programme endorsed by European Liver Patients' Association, Blue Faery, Global Liver Institute & ESDO This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content.

HCC CONNECT powered by COR2ED

701,758 Aufrufe • vor 5 Monaten

Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC) >> This is a rare and complex cancer that needs early diagnosis and intervention 📺 Watch the video from Meredith Cummins, INCA President-Elect, and CEO of NeuroEndocrine Cancer Australia, to find out: -Why urgency is needed in diagnosis & treatment -The potential of investigational treatments -Where to find support Endorsed by: INCA (NET Cancer Day). NeuroEndocrine Cancer Australia, Neuroendocrine Cancer UK #NotJustNECancer, Neuroendocrine Cancer Foundation, Neuroendocrine Cancer Research Foundation & Minkahz NETs Mission Supported by an Independent Educational Grant from Boehringer Ingelheim
5:45

Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC) >> This is a rare and complex cancer that needs early diagnosis and intervention 📺 Watch the video from Meredith Cummins, INCA President-Elect, and CEO of NeuroEndocrine Cancer Australia, to find out: -Why urgency is needed in diagnosis & treatment -The potential of investigational treatments -Where to find support Endorsed by: INCA (NET Cancer Day). NeuroEndocrine Cancer Australia, Neuroendocrine Cancer UK #NotJustNECancer, Neuroendocrine Cancer Foundation, Neuroendocrine Cancer Research Foundation & Minkahz NETs Mission Supported by an Independent Educational Grant from Boehringer Ingelheim

COR2ED

757,945 Aufrufe • vor 5 Monaten

When should early treatment intensification w/ PARPi + ARPI combination be considered for mCRPC patients? 📺 Find out in this patient case video >> You’ll also discover the SHARE Communication Framework to use with your pts in clinical practice SHARE is made up of 5 key elements: S – Success criteria & aim of treatment H – How the treatments work A – Advantages/disadvantages of each Tx option R – Risks & effective management of side effects E – Expectations for Tx success Part 1 of the highlights video in this post ~ Endorsed by Urobel & ZERO Prostate Cancer Supported by an Independent Educational Grant from AstraZeneca
5:33

When should early treatment intensification w/ PARPi + ARPI combination be considered for mCRPC patients? 📺 Find out in this patient case video >> You’ll also discover the SHARE Communication Framework to use with your pts in clinical practice SHARE is made up of 5 key elements: S – Success criteria & aim of treatment H – How the treatments work A – Advantages/disadvantages of each Tx option R – Risks & effective management of side effects E – Expectations for Tx success Part 1 of the highlights video in this post ~ Endorsed by Urobel & ZERO Prostate Cancer Supported by an Independent Educational Grant from AstraZeneca

GU CONNECT powered by COR2ED

164,512 Aufrufe • vor 5 Monaten

As we gear up for #GI26, we discussed testing and the current SoC for HER2+ advanced/metastatic GEJ/Gastric cancer with Rutika Mehta: Full discussion: ⭐️ ⭐️ ⭐️ Also on “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates
1:19

As we gear up for #GI26, we discussed testing and the current SoC for HER2+ advanced/metastatic GEJ/Gastric cancer with Rutika Mehta: Full discussion: ⭐️ ⭐️ ⭐️ Also on “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates

Oncology Brothers

11,991 Aufrufe • vor 6 Monaten